The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. (Q51470406)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Bong-Soo Cha

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Sung Hee Choi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Zheng Shan Zhao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Yong Jik Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Soo Kyung Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Dae Jung Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sung Kil Lim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Hyun Chul Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

Diabetes - Metabolism: Research and Reviews

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

411-418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

31 December 2019

cites work

1 reference

7 January 2021

Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain

1 reference

7 January 2021

Impaired beta-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM.

1 reference

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

7 January 2021

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

7 January 2021

The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes

1 reference

7 January 2021

Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.

1 reference

7 January 2021

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

1 reference

7 January 2021

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

7 January 2021

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice

1 reference

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

7 January 2021

Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.

1 reference

7 January 2021

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

1 reference

7 January 2021

Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes

1 reference

7 January 2021

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

1 reference

7 January 2021

Adult human chondrocytes cultured in alginate form a matrix similar to native human articular cartilage

1 reference

7 January 2021

Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance

1 reference

7 January 2021

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

1 reference

7 January 2021

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

7 January 2021

Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.

1 reference

7 January 2021

Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production

1 reference

7 January 2021

Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency.

1 reference

7 January 2021

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

1 reference

7 January 2021

Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus

1 reference

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

7 January 2021

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

7 January 2021

Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat.

1 reference

7 January 2021

Poor capacity for proliferation of pancreatic beta-cells in Otsuka-Long-Evans-Tokushima Fatty rat: a model of spontaneous NIDDM

1 reference

7 January 2021

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.756

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538941%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference